Johnson & Johnson (NYSE:JNJ) Stake Boosted by Baker Ellis Asset Management LLC

Baker Ellis Asset Management LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 18.5% during the 1st quarter, HoldingsChannel.com reports. The firm owned 8,779 shares of the company’s stock after purchasing an additional 1,368 shares during the period. Baker Ellis Asset Management LLC’s holdings in Johnson & Johnson were worth $1,456,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently added to or reduced their stakes in the company. Lantz Financial LLC lifted its stake in Johnson & Johnson by 3.3% in the first quarter. Lantz Financial LLC now owns 11,974 shares of the company’s stock valued at $1,986,000 after buying an additional 377 shares during the last quarter. Sulzberger Capital Advisors Inc. bought a new stake in Johnson & Johnson in the fourth quarter valued at $453,000. Horan Securities Inc. lifted its stake in Johnson & Johnson by 1.3% in the fourth quarter. Horan Securities Inc. now owns 7,178 shares of the company’s stock valued at $1,038,000 after buying an additional 90 shares during the last quarter. Strategic Financial Concepts LLC lifted its stake in Johnson & Johnson by 57.9% in the fourth quarter. Strategic Financial Concepts LLC now owns 3,467 shares of the company’s stock valued at $501,000 after buying an additional 1,271 shares during the last quarter. Finally, State of Wyoming lifted its stake in Johnson & Johnson by 205,580.0% in the fourth quarter. State of Wyoming now owns 10,284 shares of the company’s stock valued at $1,487,000 after buying an additional 10,279 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have issued reports on JNJ. Leerink Partnrs cut Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 13th. Royal Bank of Canada reissued an “outperform” rating and set a $181.00 price target on shares of Johnson & Johnson in a report on Thursday, June 5th. Bank of America lowered their price target on Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating on the stock in a report on Thursday, April 10th. Benchmark raised Johnson & Johnson to a “strong-buy” rating in a report on Thursday, April 24th. Finally, Sanford C. Bernstein reissued a “market perform” rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Eleven research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $170.88.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $155.19 on Thursday. The business’s 50-day moving average price is $153.56 and its 200 day moving average price is $153.70. The firm has a market cap of $373.41 billion, a P/E ratio of 23.34, a PEG ratio of 2.56 and a beta of 0.42. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping analysts’ consensus estimates of $2.59 by $0.18. The firm had revenue of $21.89 billion for the quarter, compared to analysts’ expectations of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. As a group, sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were paid a $1.30 dividend. The ex-dividend date was Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a yield of 3.35%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.24. Johnson & Johnson’s dividend payout ratio (DPR) is currently 57.84%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.